title: Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.
abstract: OBJECTIVE
  The vascular endothelial growth factor (VEGF) expression of podocyte is one of the well-known major factors in development of diabetic nephropathy. In this study, we investigated the effects of aldose reductase inhibitor, fidarestat on diabetic nephropathy, and renal VEGF expression in a type 1 diabetic rat model.
  
  
  METHODS
  Twenty four Sprague-Dawley male rats which were performed intraperitoneal injection of streptozotocin and normal six rats were divided into four groups including a normal control group, untreated diabetic control group, aldose reductase (AR) inhibitor (fidarestat, 16 mg kg(-1) day(-1)) treated diabetic group, and angiotensin receptor blocker (losartan, 20 mg kg(-1) day(-1)) treated diabetic group. We checked body weights and blood glucose levels monthly and measured urine albumin-creatinine ratio (ACR) at 8 and 32 weeks. We extracted the kidney to examine the renal morphology and VEGF expressions.
  
  
  RESULTS
  The ACR decreased in fidarestat and losartan treated diabetic rat groups than in untreated diabetic group (24.79 +/- 11.12, 16.11 +/- 9.95, and 84.85 +/- 91.19, p < 0.05). The renal VEGF messenger RNA (mRNA) and protein expression were significantly decreased in the fidarestat and losartan treated diabetic rat groups than in the diabetic control group.
  
  
  CONCLUSIONS
  We suggested that aldose reductase inhibitor may have preventive effect on diabetic nephropathy by reducing renal VEGF overexpression.
authors.affiliation: Department of Internal Medicine, Yonsei University Wonju College of Medicine, 162 Ilsan-dong, Wonju 220-701, Korea.
authors.forename: Joong Kyung
authors.initials: JK
authors.lastname: Sung
authors.forename: Jang Hyun
authors.initials: JH
authors.lastname: Koh
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Lee
authors.forename: Bo Hwan
authors.initials: BH
authors.lastname: Kim
authors.forename: Soo Min
authors.initials: SM
authors.lastname: Nam
authors.forename: Jae Hyun
authors.initials: JH
authors.lastname: Kim
authors.forename: Jin Hee
authors.initials: JH
authors.lastname: Yoo
authors.forename: So Hee
authors.initials: SH
authors.lastname: Kim
authors.forename: Sun Won
authors.initials: SW
authors.lastname: Hong
authors.forename: Eun Young
authors.initials: EY
authors.lastname: Lee
authors.forename: Ran
authors.initials: R
authors.lastname: Choi
authors.forename: Choon Hee
authors.initials: CH
authors.lastname: Chung
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D003928:Diabetic Nephropathies / Q000517:prevention & control; D048289:Imidazolidines / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism* / Q000473:pathology; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D042461:Vascular Endothelial Growth Factor A
chemical_list: D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D048289:Imidazolidines; D042461:Vascular Endothelial Growth Factor A; C077139:fidarestat; D000449:Aldehyde Reductase; D019808:Losartan